What is Senzime?
Senzime develops and markets CE- and FDA cleared patient monitoring systems driven by unique algorithms and sensors. Its flagship product, TetraGraph, digitally and continuously measures the degree of neuromuscular blockade in patients undergoing anesthesia. The system aims to enhance clinical precision and simplify healthcare management by preventing complications and guiding healthcare professionals in adhering to drug recommendations. This ultimately contributes to shorter hospital stays and reduced healthcare costs, aligning with the company's vision of a world free from anesthesia-related complications.
How much funding has Senzime raised?
Senzime has raised a total of $8.3M across 2 funding rounds:
Private Equity
$1.1M
Private Equity
$7.1M
Private Equity (2015): $1.2M, investors not publicly disclosed
Private Equity (2016): $7.1M, investors not publicly disclosed
What's next for Senzime?
With the recent major strategic investment, Senzime is poised for significant scaling and market penetration. The enterprise-level funding suggests a transition towards broader commercialization and potentially further research and development into advanced patient monitoring solutions. The company's focus on improving clinical outcomes and reducing healthcare expenditures positions it favorably within the growing markets for patient monitoring systems in Europe and the United States, which are collectively valued at over SEK 15 billion. Future developments will likely concentrate on expanding the reach of TetraGraph and exploring new applications for its proprietary technology.
See full Senzime company page
